You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 15, April 16, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (95)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Critical Care/ Intensive Care Medicine
 •Hematology, Other
 •Immunology, Other
 •Alert me on articles by topic

Clinical Outcomes Following Institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions

Paul C. Hébert, MD, MHSc; Dean Fergusson, MHA; Morris A. Blajchman, MD; George A. Wells, PhD; Andrew Kmetic, MSc; Doug Coyle, MSc; Nancy Heddle, MSc; Marc Germain, MD, PhD; Mindy Goldman, MD; Baldwin Toye, MD; Irwin Schweitzer, MSc; Carl vanWalraven, MD, MSc; Dana Devine, PhD; Graham D. Sher, MD, PhD; for the Leukoreduction Study Investigators

JAMA. 2003;289:1941-1949.

Context  A number of countries have implemented a policy of universal leukoreduction of their blood supply, but the potential role of leukoreduction in decreasing postoperative mortality and infection is unclear.

Objective  To evaluate clinical outcomes following adoption of a national universal prestorage leukoreduction program for blood transfusions.

Design, Setting, and Population  Retrospective before-and-after cohort study conducted from August 1998 to August 2000 in 23 academic and community hospitals throughout Canada, enrolling 14 786 patients who received red blood cell transfusions following cardiac surgery or repair of hip fracture, or who required intensive care following a surgical intervention or multiple trauma.

Intervention  Universal prestorage leukoreduction program introduced by 2 Canadian blood agencies. A total of 6982 patients were enrolled during the control period and 7804 patients were enrolled following prestorage leukoreduction.

Main Outcome Measures  All-cause in-hospital mortality and serious nosocomial infections (pneumonia, bacteremia, septic shock, all surgical site infections) occurring after first transfusion and at least 2 days after index procedure or intensive care unit admission. Secondary outcomes included rates of posttransfusion fever and antibiotic use.

Results  Unadjusted in-hospital mortality rates were significantly lower following the introduction of leukoreduction compared with the control period (6.19% vs 7.03%, respectively; P = .04). Compared with the control period, the adjusted odds of death following leukoreduction were reduced (odds ratio [OR], 0.87; 95% confidence interval [CI], 0.75-0.99), but serious nosocomial infections did not decrease (adjusted OR, 0.97; 95% CI, 0.87-1.09). The frequency of posttransfusion fevers decreased significantly following leukoreduction (adjusted OR, 0.86; 95% CI, 0.79-0.94), as did antibiotic use (adjusted OR, 0.90; 95% CI, 0.82-0.99).

Conclusion  A national universal leukoreduction program is potentially associated with decreased mortality as well as decreased fever episodes and antibiotic use after red blood cell transfusion in high-risk patients.


Author Affiliations: University of Ottawa Centre for Transfusion Research, and Clinical Epidemiology Program of the Ottawa Health Research Institute, Ottawa, Ontario (Drs Hébert and Wells, and Mssrs Fergusson, Kmetic, and Schweitzer); Department of Pathology, McMaster University and Canadian Blood Services, Hamilton, Ontario (Dr Blajchman); Clinical Epidemiology Program of the Ottawa Health Research Institute and the Department of Medicine, University of Ottawa, Ottawa, Ontario (Dr vanWalraven and Mr Coyle); Department of Medicine, McMaster University (Ms Heddle); Héma Québec, Québec City (Dr Germain); Héma Québec, Montréal (Dr Goldman);Department of Pathology and Laboratory Medicine, University of Ottawa (Dr Toye); Canadian Blood Services, Vancouver, British Columbia (Dr Devine); and Canadian Blood Services, Ottawa (Dr Sher).


RELATED LETTER

Leukoreduction vs Buffy-Coat Depletion and the Safety of Blood Transfusion
Jonathan P. Wallis
JAMA. 2003;290(12):1580.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Clinical Outcomes Following Institution of Universal Leukoreduction of Blood Transfusions for Premature Infants
Dean Fergusson, Paul C. Hébert, Shoo K. Lee, C. Robin Walker, Keith J. Barrington, Lawrence Joseph, Morris A. Blajchman, and Stan Shapiro
JAMA. 2003;289(15):1950-1956.
ABSTRACT | FULL TEXT  

Is Leukoreduction of Blood Components for Everyone?
Howard L. Corwin and James P. AuBuchon
JAMA. 2003;289(15):1993-1995.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention and treatment of post-traumatic acute respiratory distress syndrome
Benfield et al.
Trauma 2007;9:255-266.
ABSTRACT  

Association of RBC Transfusion With Mortality in Patients With Acute Lung Injury
Netzer et al.
Chest 2007;132:1116-1123.
ABSTRACT | FULL TEXT  

Controversies in RBC Transfusion in the Critically Ill
Hebert et al.
Chest 2007;131:1583-1590.
ABSTRACT | FULL TEXT  

Anaemia during critical illness
Walsh and Saleh
Br J Anaesth 2006;97:278-291.
FULL TEXT  

Intensive care and emergency medicine: progress over the past 25 years.
Vincent et al.
Chest 2006;129:1061-1067.
ABSTRACT | FULL TEXT  

Prestorage Leukoreduction Prevents Accumulation of Matrix Metalloproteinase 9 in Stored Blood
Frake et al.
Arch Surg 2006;141:396-400.
ABSTRACT | FULL TEXT  

Anemia in the Long-term Ventilator-Dependent Patient With Respiratory Failure
Silver
Chest 2005;128:568S-575S.
ABSTRACT | FULL TEXT  

Understanding the Consequences of Transfusion-Related Acute Lung Injury
Shander and Popovsky
Chest 2005;128:598S-604S.
ABSTRACT | FULL TEXT  

Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications
Madjdpour and Spahn
Br J Anaesth 2005;95:33-42.
ABSTRACT | FULL TEXT  

Transfusion rates vary significantly amongst Canadian medical centres: [Les taux de transfusion varient de facon significative dans les centres medicaux canadiens]
Hutton et al.
Canadian J. Anesthesia 2005;52:581-590.
ABSTRACT | FULL TEXT  

Transfusion Practice and Blood Stream Infections in Critically Ill Patients
Shorr et al.
Chest 2005;127:1722-1728.
ABSTRACT | FULL TEXT  

Anemia, Allogenic Blood Transfusion, and Immunomodulation in the Critically Ill
Raghavan and Marik
Chest 2005;127:295-307.
ABSTRACT | FULL TEXT  

Medical management of patients with multiple organ dysfunction arising from acute radiation syndrome
Jackson et al.
Br. J. Radiol. 2005;Supplement_27:161-168.
ABSTRACT | FULL TEXT  

Do Transfusions Get to the Heart of the Matter?
Hebert and Fergusson
JAMA 2004;292:1610-1612.
FULL TEXT  

Evidence-Based Medicine in the ICU: Important Advances and Limitations
Vincent
Chest 2004;126:592-600.
ABSTRACT | FULL TEXT  

Transfusion-Related Acute Lung Injury: A Review
Looney et al.
Chest 2004;126:249-258.
ABSTRACT | FULL TEXT  

Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group
Waselenko et al.
ANN INTERN MED 2004;140:1037-1051.
ABSTRACT | FULL TEXT  

Double-Blind, Randomized Controlled Trial on the Effect of Leukocyte-Depleted Erythrocyte Transfusions in Cardiac Valve Surgery
Bilgin et al.
Circulation 2004;109:2755-2760.
ABSTRACT | FULL TEXT  

Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery
van Hilten et al.
BMJ 2004;328:1281.
ABSTRACT | FULL TEXT  

Will we ever know if leukoreduction of red blood cells should be performed?/Saurons-nous un jour s'il faut proceder a la reduction leucocytaire des culots globulaires ?
Carson and Berlin
Canadian J. Anesthesia 2004;51:407-410.
FULL TEXT  

Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials: [La transfusion de sang reduit en leucocytes peut diminuer les infections postoperatoires : deux meta-analyses d'etudes randomisees et controlees]
Fergusson et al.
Canadian J. Anesthesia 2004;51:417-424.
ABSTRACT | FULL TEXT  

Leukoreduction vs Buffy-Coat Depletion and the Safety of Blood Transfusion
Wallis
JAMA 2003;290:1580-1580.
FULL TEXT  

Is Leukoreduction of Blood Components for Everyone?
Corwin and AuBuchon
JAMA 2003;289:1993-1995.
FULL TEXT  

The Hematologist and Radiation Casualties
Dainiak et al.
ASH Education Book 2003;2003:473-496.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.